Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Comera Life Sciences Holdings, Inc.CMRA · Entity 94670 | Director | November 07, 2023 | November 13, 2023 |
| Ernexa Therapeutics Inc.ERNA · Entity 8278 | Director · General Counsel | January 01, 2024 | January 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Comera Life Sciences Holdings, Inc.
Report date November 07, 2023 · Filed November 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to PurchaseSEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2033-11-07 | Direct | 14,200 |
Reported balance
After 2023-11-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-07 · Grant · Acquired 14,200 · Balance 14,200 F1: Granted pursuant to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan. The stock option shall vest over three (3) years, with one-third of the shares of common stock underlying the option vesting on November 7, 2024, and the remainder vesting in equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan. The stock option shall vest over three (3) years, with one-third of the shares of common stock underlying the option vesting on November 7, 2024, and the remainder vesting in equal monthly installments thereafter.
Ernexa Therapeutics Inc.
Report date January 01, 2024 · Filed January 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2034-01-01 | Direct | 168,521 |
Reported balance
After 2024-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-01 · Grant · Acquired 168,521 · Balance 168,521 F1: Subject to continued service, 25% of the shares underlying the stock option will vest on the nine-month anniversary of the grant date, and the remaining shares underlying the stock option will vest in 39 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued service, 25% of the shares underlying the stock option will vest on the nine-month anniversary of the grant date, and the remaining shares underlying the stock option will vest in 39 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2024 Filed Jan 3, 2024 22:01 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | GrantStock Option (right to buy) · Derivative | 168,521 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001140361-24-000468 · form4.xml · derivative · entry 1 Clarke Dorothy J · CIK 0001992152 · Director · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,521 Underlying: Common Stock, par value $0.005 per share · 168,521 shares Expires 2034-01-01 F1 · derivative.exercise_date: Subject to continued service, 25% of the shares underlying the stock option will vest on the nine-month anniversary of the grant date, and the remaining shares underlying the stock option will vest in 39 substantially equal monthly installments thereafter. Read SEC document |
| November 07, 2023 Filed Nov 13, 2023 06:31 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | GrantStock Option (Right to Purchase · Derivative | 14,200 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001062993-23-020478 · form4.xml · derivative · entry 1 Clarke Dorothy J · CIK 0001992152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,200 Underlying: Common Stock · 14,200 shares Expires 2033-11-07 F1 · derivative.exercise_date: Granted pursuant to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan. The stock option shall vest over three (3) years, with one-third of the shares of common stock underlying the option vesting on November 7, 2024, and the remainder vesting in equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.